Research

The UK DRI at UCL takes a novel approach by integrating diverse expertise from genetics to clinics, with the aim of finding treatments quicker. Through improving understanding of the earliest stages of neurodegeneration, the team seeks to identify new drug targets, develop therapeutics, and deliver them at an early stage in disease progression when they are most likely to be effective. 

Our researchers aim to better understand the complexity and diversity of neurodegenerative diseases, to intervene and improve the outlook for people affected by these conditions. 

We know that for the majority of neurodegenerative conditions, harmful changes to the brain begin decades before symptoms appear. To stand a better chance of slowing or stopping disease progression, we need to intervene with treatments at the earliest stages. 

The UK DRI at UCL host the UK DRI Biomarker Factory, the Single Cell and Spatial Omics Facility, Microscopy Facilities and the UK DRI Data Science and Infomatics Platform.

The Centre is located within London’s dynamic Knowledge Quarter and closely linked to UCL’s world-class Dementia Research Centre and the Queen Square Brain Bank. Work is underway on a state-of-the-art world-class centre for translational neuroscience, which will house over 500 researchers from the UK Dementia Research Institute and UCL’s Queen Square Institute of Neurology. 

Find out more about the research that takes place at UK DRI at UCL.